The in vitro fertilization market size is projected to be USD 28.55 billion in 2025, USD 30.90 billion in 2026, and reach USD 45.90 billion by 2031, growing at a CAGR of 8.28% from 2026 to 2031. This report is Segmented by Product (Reagents & Media, Instruments, Consumables & Disposables), Cycle Type (Fresh IVF Cycles - Non-Donor, and More), Procedure Type (Conventional IVF, IVF With ICSI, IVF With PGT/PGD, and More), End User (Fertility Clinics, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD)
Other drivers and restraints analyzed in the detailed report include:
A broader push for contamination control drives demand for closed vitrification devices and pre-sterilized culture dishes. Hamilton Thorne integrates laser-assisted hatching into catheter tips, blending instrument functionality with recurring disposable income. Suppliers bundle service contracts and replacement parts to lock in clinics for five-year terms, creating high switching costs. As manufacturing scales, unit prices fall, enlarging adoption among mid-volume centers and sustaining the in vitro fertilization market.
Fresh non-donor cycles retained 34.2% revenue in 2025 owing to patient preference for autologous gametes and lower lab fees versus donor options. Yet donor egg cycles rise at a 10.98% CAGR, the highest within this category, benefiting from legal liberalization in Japan and persistent demand among women over 40. In Spain, donor egg revenues hit EUR 180 million (USD 195 million) in 2024, fueled by cross-border inflows. The in vitro fertilization market share for donor eggs is projected to reach double-digits by 2031.
Thawed-embryo cycles benefit from 95% post-vitrification survival, letting clinics adopt segmented stimulation strategies that minimize ovarian hyperstimulation risk. Cryobanks invest in genetic panels covering 300 inherited conditions, raising perceived quality and allowing premium pricing. Clinics that build or partner with egg banks secure supply and margin, while regulation remains a wild card as anonymity rules evolve across Europe and Asia-Pacific.
Europe maintains steady growth as national health systems subsidize treatment and liberal gamete-donor laws attract cross-border patients. Spain and the Czech Republic serve as donor-egg hubs, and clinics leverage multilingual staff to capture demand. Germany’s 2025 consultation on legalizing egg donation could repatriate outbound spend. Regulatory alignment under the IVDR lengthens approval cycles for genetic-testing add-ons, yet once cleared, uniform rules simplify rollout across member states.
Asia-Pacific posts the highest 9.32% CAGR to 2031. China completed 530,000 cycles in 2024, up 22% year on year, after easing private-clinic licensing and broadening insurance coverage under urban employee plans. Japan’s JPY 300,000 (USD 2,000) subsidy stimulates uptake among women under 43, while India’s tier-2 cities witness rapid chain expansion targeting the middle class. Localization of culture-media production in Singapore and domestic catheter molding plants in China mitigates shipping delays and import duties, further energizing the in vitro fertilization market.
Global In Vitro Fertilization Market Trends and Insights
Rising Infertility Prevalence and Diagnosis Rates
Roughly 17.5% of adults now face infertility, a rise from 15% in 2010, according to a 2025 World Health Organization update. Improved diagnostic coverage uncovers previously hidden cases, especially in India, where district hospitals added infertility screening under the National Health Mission in 2024. In the United States, 13.4% of women aged 15-49 experienced impaired fecundity in 2024, up from 12.1% in 2015, amid higher obesity rates and endocrine-disruptor exposure. The in vitro fertilization market benefits because diagnosed patients are more likely to pursue treatment. Clinics respond by scaling laboratory capacity and frozen-storage infrastructure to absorb volume. As stigma eases and subsidies rise, pent-up demand continues to convert into active treatment cycles, lifting procedure counts in developing economies.Increasing Average Maternal Age at First Birth
Mean maternal age at first birth reached 28.2 years in the United States in 2023 and climbed to nearly 30 years in several OECD members, a demographic tilt that inflates cycle volumes because older patients require more attempts for success. Japan reported that 29.8% of first births occurred to mothers aged 35 or older in 2024, prompting subsidy ceilings to rise to JPY 300,000 (USD 2,000) per cycle. Clinics, therefore, diversify stimulation protocols, offering mini-IVF to manage diminished ovarian reserve while protecting live-birth outcomes. The in vitro fertilization market embeds these age-driven treatments as core growth, particularly in East Asia and Southern Europe, where delayed childbearing is widespread. Equipment makers emphasize gentle stimulation monitoring tools to attract this expanding demographic.Other drivers and restraints analyzed in the detailed report include:
- Technological Leaps in Cryopreservation & Culture Media
- Expansion of Cross-Border Fertility Tourism Networks
- High Treatment Cost and Patchy Insurance Reimbursement
- Supply-Chain Vulnerability in Specialty Reagents & Plastics
Segment Analysis
In 2025, instruments generated 55.2% of revenue, illustrating capital intensity in IVF laboratories where incubators, micromanipulators, and laser systems dominate budgets. Vitrolife’s EmbryoScope time-lapse incubator, priced at USD 80,000-120,000, anchors this premium tier. Consumables & disposables, however, post the fastest 10.21% CAGR to 2031 as clinics shift toward single-use catheters under tighter sterility rules. The in vitro fertilization market size for consumables is projected to account for one-third of incremental revenue gains through 2031. Regulatory pressure to validate cleaning procedures for reusable equipment accelerates the switch to disposables, while private-equity investors favor the predictable reorder cycle attached to consumable sales.A broader push for contamination control drives demand for closed vitrification devices and pre-sterilized culture dishes. Hamilton Thorne integrates laser-assisted hatching into catheter tips, blending instrument functionality with recurring disposable income. Suppliers bundle service contracts and replacement parts to lock in clinics for five-year terms, creating high switching costs. As manufacturing scales, unit prices fall, enlarging adoption among mid-volume centers and sustaining the in vitro fertilization market.
Fresh non-donor cycles retained 34.2% revenue in 2025 owing to patient preference for autologous gametes and lower lab fees versus donor options. Yet donor egg cycles rise at a 10.98% CAGR, the highest within this category, benefiting from legal liberalization in Japan and persistent demand among women over 40. In Spain, donor egg revenues hit EUR 180 million (USD 195 million) in 2024, fueled by cross-border inflows. The in vitro fertilization market share for donor eggs is projected to reach double-digits by 2031.
Thawed-embryo cycles benefit from 95% post-vitrification survival, letting clinics adopt segmented stimulation strategies that minimize ovarian hyperstimulation risk. Cryobanks invest in genetic panels covering 300 inherited conditions, raising perceived quality and allowing premium pricing. Clinics that build or partner with egg banks secure supply and margin, while regulation remains a wild card as anonymity rules evolve across Europe and Asia-Pacific.
Complete Report Scope:
- By Product
- Reagents & Media
- Culture Media
- Cryopreservation Media
- Semen Processing Media
- Instruments
- Imaging Systems
- Incubators & Time-Lapse Chambers
- Cryosystems (LN₂ Tanks, Freezers)
- IVF Workstations & Clean-Air Cabinets
- Ovum Aspiration Pumps
- Sperm Separation Systems
- Micromanipulator Systems
- Other Instruments
- Consumables & Disposables
- Pipettes & Tips
- Catheters & Needles
- Culture Dishes & Slides
- Embryo Transfer Sets
- Reagents & Media
- By Cycle Type
- Fresh IVF Cycles - Non-Donor
- Thawed / Frozen IVF Cycles - Non-Donor
- Donor Egg IVF Cycles
- Donor Sperm IVF Cycles
- By Procedure Type
- Conventional IVF
- IVF with ICSI
- IVF with PGT/PGD
- Mini-IVF & Natural-Cycle IVF
- By End User
- Fertility Clinics
- Hospitals & Surgical Centers
- Cryobanks & Research Laboratories
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America delivered 43.1% of revenue in 2025, buoyed by 330,000 U.S. cycles performed in 2024 and expanding state mandates in California, Colorado, and New York. Employer-funded benefits and high disposable income sustain premium add-on adoption, including PGT and AI grading. Canada’s single-cycle provincial coverage drives early uptake, though many patients pay for subsequent attempts, supporting the in vitro fertilization market. Suppliers focus on regulatory compliance and bundled service contracts to protect their share amid competition from lower-priced imports.Europe maintains steady growth as national health systems subsidize treatment and liberal gamete-donor laws attract cross-border patients. Spain and the Czech Republic serve as donor-egg hubs, and clinics leverage multilingual staff to capture demand. Germany’s 2025 consultation on legalizing egg donation could repatriate outbound spend. Regulatory alignment under the IVDR lengthens approval cycles for genetic-testing add-ons, yet once cleared, uniform rules simplify rollout across member states.
Asia-Pacific posts the highest 9.32% CAGR to 2031. China completed 530,000 cycles in 2024, up 22% year on year, after easing private-clinic licensing and broadening insurance coverage under urban employee plans. Japan’s JPY 300,000 (USD 2,000) subsidy stimulates uptake among women under 43, while India’s tier-2 cities witness rapid chain expansion targeting the middle class. Localization of culture-media production in Singapore and domestic catheter molding plants in China mitigates shipping delays and import duties, further energizing the in vitro fertilization market.
List of Companies Covered in this Report:
- Cook Group
- The Cooper Companies
- Merck
- Vitrolife
- Thermo Fisher Scientific
- Hamilton Thorne
- FUJIFILM
- Nikon
- Illumina
- Agilent Technologies
- Natera
- Kitazato Corp.
- Esco Lifesciences
- Ferring Pharmaceuticals
- Genea Biomedx
- INVO Bioscience
- Rocket Medical
- Oxford Gene Technology (Sysmex)
- Boston IVF
- IVI RMA Global
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Cook Group
- CooperSurgical
- Merck KGaA (EMD Serono)
- Vitrolife
- Thermo Fisher Scientific
- Hamilton Thorne
- FUJIFILM Irvine Scientific
- Nikon
- Illumina
- Agilent Technologies
- Natera
- Kitazato Corp.
- Esco Micro
- Ferring Pharmaceuticals
- Genea Biomedx
- INVO Bioscience
- Rocket Medical PLC
- Oxford Gene Technology (Sysmex)
- Boston IVF
- IVI RMA Global
